Je was op zoek naar: tromboembolijo (Sloveens - Engels)

zato imajo zlasti kadilke zvišano tveganje za tromboembolijo.
therefore, especially in women who smoke, there is an increased risk for thromboembolism.

antikoagulacija pri odraslih bolnikih s hit tipa ii in tromboembolijo:
anticoagulation in adult patients with hit type ii and thromboembolic disease:

tveganje za vensko tromboembolijo se pri ženskah, ki uporabljajo kombinirane kontraceptive, povečuje s:
the risk of venous thromboembolism in combined contraceptives users increases with:

najbolj resni stranski učinki vključujejo anemijo, trombocitopenijo, levkocitozo, nevrološke motnje in tromboembolijo.
most serious side effects include anaemia, thrombocytopenia, leukocytosis, neurological disorders and thromboembolism.

upoštevati moramo zvečano tveganje za tromboembolijo v poporodni dobi (glejte poglavje 4. 6).
the increased risk for thromboembolism in the puerperium must be considered (see section 4.6).

zelo redko (< 0,01 %) so poročali o občasnih povezavah med zdravljenjem z olanzapinom in vensko tromboembolijo.
temporal association of olanzapine treatment and venous thromboembolism been reported uncommonly (≥ 0.1% and < 1%).

trombembolija zelo redko (< 0, 01%) so poročali o občasnih povezavah med zdravljenjem z olanzapinom in vensko tromboembolijo.
thromboembolism temporal association of olanzapine treatment and venous thromboembolism has very rarely (< 0.01%) been reported.

zdravilo refludan so preučevali v dveh glavnih študijah, v katerih je sodelovalo 198 bolnikov, med katerimi jih je 125 imelo hit in tromboembolijo.
refludan has been studied in two main studies involving 198 patients, 125 of whom had hit and thromboembolic disease.

pojavi se lahko povečano tveganje tromboembolije, še posebej pri bolnikih z dolgotrajno imobilizacijo, po večji operaciji in pri ostalih faktorjih tveganja za tromboembolijo.
there may be an increase in the risk of thrombo-embolic events especially in patients with prolonged immobilization, post major surgery and other thromboembolic risk factors.

antikoagulacija pri odraslih bolnikih, ki imajo s heparinom inducirano trombocitopenijo (hit) tipa ii in tromboembolijo, ki zahteva parenteralno antitrombotično zdravljenje.
anticoagulation in adult patients with heparin-induced thrombocytopenia (hit) type ii and thromboembolic disease mandating parenteral antithrombotic therapy.

pri zdravljenju prirojenega pomanjkanja antitrombina je treba odmerek in trajanje zdravljenja prilagoditi posameznemu bolniku ob upoštevanju družinske anamneze, povezane s tromboembolijo, ter upoštevanju dejanskih dejavnikov kliničnega tveganja in laboratorijske ocene.
in the treatment of congenital antithrombin deficiency, the dose and duration of treatment should be individualised for each patient taking into account the family history with regard to thromboembolic events, the actual clinical risk factors, and the laboratory assessment.

refludan se uporablja za antikoagulacijo pri odraslih bolnikih, ki imajo s heparinom izzvano trombocitopenijo (hit) tipa ii in tromboembolijo, ki zahteva zdravljenje z injekcijami antitrombotikov.
refludan is used for anticoagulation in adult patients with heparin-induced thrombocytopenia (hit) type ii and thromboembolic disease requiring injected antithrombotic medicines.

vendar, ker imajo bolniki s shizofrenijo pogosto prisotne pridobljene dejavnike tveganja za vensko tromboembolijo, je treba ugotoviti vse možne dejavnike tveganja za vte, kot npr. imobilizacija bolnikov ter izvesti preventivne ukrepe.
however, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of vte e.g. immobilisation of patients, should be identified and preventive measures undertaken.

pri indikaciji hit tipa ii s tromboembolijo (125 bolnikov) je skupna umrljivost v času raziskave znašala približno 9 %, medtem ko so amputacije zabeležili pri 6 %, nove tromboembolične zaplete pa pri 10 % bolnikov.
in the indication hit type ii with thromboembolic disease (125 patients) the overall mortality during the study period was approximately 9 % while amputations and new thromboembolic complications were recorded in 6 % and 10 %, respectively.